Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2024Cardiovascular DiabetologyOpen Access

Is GFR decline induced by SGLT2 inhibitor of clinical importance?

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMerve Günes-AltanABAgnes BoschKSKristina Striepe

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Günes-Altan et al. (2024) studied this question.

synapsesocial.com/papers/68e67e05b6db6435876070dbhttps://doi.org/10.1186/s12933-024-02223-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging2019 · 280 citations
  2. 2The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus2014 · 472 citations
  3. 3The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial2022 · 61 citations
  4. 4Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017 · 7,908 citations
  5. 5Empagliflozin in Patients with Chronic Kidney Disease2022 · 2,636 citations